GLUE
HealthcareMonte Rosa Therapeutics, Inc.
$14.40
$-0.91 (-5.94%)
Jan 5, 2026
Price History (1Y)
Analysis
Monte Rosa Therapeutics, Inc. is a biotechnology company operating in the healthcare sector. With a market capitalization of $937.70 million and annual revenue of $181.54 million, it has a notable presence in its industry. The company employs 147 individuals. The financial health of Monte Rosa Therapeutics appears to be positive, with a gross margin of 28.1% and a profit margin of 11.5%. However, the operating margin is significantly negative at -258.3%. In terms of returns, the company has a return on equity (ROE) of 9.3% and a return on assets (ROA) of 1.4%. The balance sheet indicates that Monte Rosa Therapeutics has $391.26 million in cash and $40.17 million in debt, resulting in a debt-to-equity ratio of 16.34. Monte Rosa Therapeutics' valuation context is notable, with a P/E ratio (TTM) of 48.00 and a forward P/E of -10.92. The revenue growth rate over the past year was 38.5%, although earnings growth data is not available. Dividend information is also unavailable for the company.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $937.70M
- P/E Ratio
- 48.00
- 52-Week High
- $19.17
- 52-Week Low
- $3.50
- Avg Volume
- 1.12M
- Beta
- 1.60
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 147